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1. Introduction
1.1. Rationale of neoadjuvant chemotherapy in treatment of breast cancer
Neoadjuvant chemotherapy (NAC), also termed as preoperative, induction or primary che‐
motherapy, is defined as the administration of systemic chemotherapeutic agent prior to lo‐
cal control of surgery or radiation. Giving chemotherapy before performing a resection of
tumour was initially introduced in locally advanced breast cancer where large inoperable
tumour can be converted to operable cancer.
Moreover, at the time of breast cancer diagnosed with 2 to 3 cm in size, the risk of occult
metastasis either in axillary lymph node or distant micrometastasis is greater than 50% [1],
[2]. There were some evidences demonstrated in animal model that after surgical removal of
primary cancer, metastases might be exacerbated [3], [4]. The administration of systemic che‐
motherapy in this setting might be a benefit to decrease the mortality risk from systemic
spreading of the disease. Therefore, control of the disease prior to surgical treatment might
produce a better treatment outcome. It was debated that NAC might delay the operation.
However, the result from many studies showed that during the course of NAC breast cancer
rarely progressed, or if it progressed that likely reflected the aggressive tumour which did
not response to chemotherapy postoperatively.
Another main benefit of NAC is monitoring response to the treatment, so as a good model
for in vivo test for the cytotoxic agents. The good response to NAC with complete pathologi‐
cal response (pCR) is a surrogate marker for overall survival. Recent advance in develop‐
ment of high potential but less toxicity chemotherapy as well as other targeted therapy has
brought to higher rate of pCR. Significantly double increased rates of pCR was documented
in breast cancer women who had docetaxel following 4 cycles of anthracycline-based NAC
treatment, though overall survival (OS) was affected only if pCR in the breast and axillary
nodes was achieved [5], [6]. The pCR rate was even higher in the addition of trastuzumab
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and pertuzumab [7]. However, with recent breast cancer subtypes identifying by estrogen
receptor (ER), progesterone receptor (PR) and HER-2 expression status documented in the
recent St. Gallen guideline [8], pCR is likely associated with only in non-luminal subtype [9].
Furthermore, increased rate of breast conserving surgery (BCS) was documented in operable
breast cancer with lower risk of local recurrence, in particular when pCR was achieved [10].
2. Neoadjuvant chemotherapy versus adjuvant chemotherapy
Preoperative or NAC has been compared with standard adjuvant chemotherapy as the treat‐
ment of breast cancer in several phase III studies. The primary end points mainly are dis‐
ease-free survival (DFS) and OS. These studies showed that using the chemotherapy
preoperatively did not improve DFS and OS, compared with using the same regimen as an
adjuvant treatment. A pivotal study from the National Surgical Adjuvant Breast and Bowel
Project (NSABP18) [11] compared the use of neoadjuvant adriamycin plus cyclophospha‐
mide (AC) with the same regimen administering postoperatively. With 4-cycle of neoadju‐
vant AC, the complete clinical response rate (cCR) and pathological complete response rate
(pCR) were 36% and 13%, respectively. In primarily operable breast cancer, NAC can down‐
stage tumor and lead to small increase of breast conserving rate (60% vs 67%, p = 0.002). Al‐
though substantial response was found with neoadjuvant approach, there was no
statistically significant difference in terms of DFS and OS at a 9-year follow up [12]. Another
study from the European Organization for Research and Treatment of Cancer (EORTC)
compared the efficacy of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) preopera‐
tively or postoperatively [13]. Consistent with the NSABP-B18 trial, the OS, PFS and relapse
rate were similar between both groups. Also, several smaller studies exploring the benefit of
NAC did not find any survival benefit for the neoadjuvant approach [13]-[15].
Recent meta-analysis addressed directly the benefit of neoadjuvant versus adjuvant chemo‐
therapy [16]. This meta-analysis included nine randomized trials with the total of 3946 pa‐
tients. There was no difference of death and disease progression. Surprisingly, the patients
who received neoadjuvant treatment experienced higher local relapse (risk ratio of 1.22,
p=0.015). This greater risk of local recurrence mainly occurred in the trials that the patients
received radiotherapy without surgery in patients who achieved clinical complete response.
To date, the evidence-based literatures support the benefit of NAC as an approach to con‐
vert inoperable breast cancer to an operable tumor, or downstaging to increase breast con‐
serving rate. These seems to be no difference in survival in patients with operable breast
cancer whether chemotherapy is given before or after surgery.
3. Types of neoadjuvant chemotherapy for breast cancer
There was no inherent reason to believe that a regimen that works postoperatively will not
work preoperatively. Therefore, a standard neoadjuvant regimen is an acceptable postopera‐
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tive regimen. Previously, anthracycline-based chemotherapy was approved as standard of
care for adjuvant treatment of operable breast cancer. It is justified to use at least three to
four cycles of anthracycline-based regimen and additional cycles may be considered to max‐
imize response. Later, combination of taxane and anthracycline using as an adjuvant treat‐
ment has been proven to be superior to anthracycline alone and become a standard of care
in node-positive and high-risk node negative breast cancer. Therefore, several clinical trials
have explored the different chemotherapy combinations using as the primary systemic treat‐
ment. The best type and schedule administration of preoperative taxanes were investigated
in several phase III studies.
The study of NSABP-B27 is the largest study to demonstrate the benefit of adding docetaxel
to anthracycine-based regimen [17]. Over 2000 patients were randomized to receive 1) 4 cy‐
cles of preoperative AC, 2) 4 cycles of neoadjuvant AC followed by 4 cycles of docetaxel and
then surgery, and 3) 4 cycles of AC followed by surgery and then 4 cycles of adjuvant doce‐
taxel. The results showed superiority of clinical response, pCR in patients who received the
addition of docetaxel preoperatively (14% vs 26%, p<0.001), but similar breast conserving
rate (63% vs 62%). Furthermore, adding docetaxel either preoperatively or postoperatively
modestly reduced local recurrence rate with comparable DFS and OS [6].
In the Aberdeen trial, the locally-advanced breast cancer patients were initially treated with
4 cycles of the combination of cyclophosphamide, vincristine, adriamycin and prednisolone
(CVAP). The patients who had response to CVAP were randomized to receive another 4 cy‐
cles of CVAP or 4 cycles of docetaxel. Among total 162 patients, 66 percent experienced clin‐
ical response following the CVAP. Of these, changing to docetaxel provided much better
response rate (85% vs 64%, p=0.03), pCR rate (31% vs 15%, p=0.06) and 5-year survival rate
(97% vs 78%, p=0.04) [18] .
Numerous trials have addressed to answer how best to incorporate taxane to anthracycline-
based regimen. The German Preoperative Adriamycin and Docetaxel study II (GEPAR-
DUO) [19] and the Arbeitsgemeinschaft Gastroenterologische Onkologie (AGO) study [20]
explored whether using taxane sequentially or concurrently with anthracycline is the best
approach. Both studies demonstrate significantly higher pCR and breast conserving rate in
sequential arm. However, it is impossible to demonstrate that the better outcome of sequen‐
tial arm is a result of sequential use itself or the higher cumulative dose of chemotherapy
and longer duration of treatment with sequential administration. Another randomized
study compared the efficacy of paclitaxel administered either weekly or every 3 weeks
schedules, followed by the combination of 5-FU, adriamycin and cyclophosphamide (FAC).
Weekly schedule associated with better pCR and also breast conserving rates [21].
Taken together, these data support the sequential use of anthracycline and taxane as the ne‐
oadjuvant treatment in both locally advanced and operable breast cancer. However, the us‐
age of taxane in low-risk patients or ER-positive patients may provide minimal benefit
outrage of the risk of adverse effect. Optimizing chemotherapy regimen should be consid‐
ered individually based on reliable prognostic factor, patient’s status and their preference af‐
ter discussing of the risk and benefit of the treatment.
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The patients who achieve poor response to initial neoadjuvant chemotherapy, i.e non-res‐
ponder, have a worse prognosis. Modification of chemotherapy after observing poor re‐
sponse has not resulted in better outcome [22], [24]. In the German Preoperative Adriamycin
and Docetaxel Study III (GEPAR-TRIO) study [22], the breast cancer patients who had poor
response to 2 cycles of neoadjuvant docetaxel, adriamycin and cyclophosphamide (TAC)
were randomized to receive another 4 cycles of TAC or alter to 4 cycles of vinorelbine plus
capecitabine (NX). The results showed no difference in terms of breast conserving rate, clini‐
cal and pathological response. On the other hand, in the Aberdeen trial, the patients who
received docetaxel after achieving poor respond to 4 cycles of cyclophosphamide, vincris‐
tine, doxorubicin and prednisolone (CVAP) ultimately had substantial overall response rate
(66%) [25]. On the basis of limited benefit to neoadjuvant chemotherapy in non-responders,
adjuvant therapy such as hormonal treatment as well as targeted therapy is considered as
the standard treatment to improve outcome [26].
4. Other neoadjuvant therapies in treatment of breast cancer: evidence-
based information
4.1. Neoadjuvant therapy for HER2-positive breast cancer
Overexpression of human epidermal growth factor receptor (HER2) is found in approximate
20-30 percent of breast cancer. Trastuzumab, a humanized antibody against HER2, com‐
bined with chemotherapy improved survival in metastatic HER2-positive breast cancer [27].
Moreover, 1-year of adjuvant trastuzumab has been established as standard treatment in
HER2-positive breast cancer based on improvement of overall survival in several studies
[28], [29]. With the promising activity of trastuzumab, its combination with neoadjuvant
chemotherapy to enhance response has been proposed. There were several small phase II
trials explored different combination of preoperative trastuzumab and chemotherapy. The
pCR rate ranged from 12-45% [30], [31]. To date, there was a randomized controlled trial
evaluated the efficacy of preoperative trastuzumab combined with anthracycline-based che‐
motherapy [32]. The stage II and III HER2-positive breast cancer patients were treated with
4 cycles of paclitaxel followed by 4 cycles of 5-fluorouracil, epirubicin and cyclophospha‐
mide (FEC) with or without trastuzumab. The patients in trastuzumab arm had significantly
higher pCR rate (65% vs 26%, p=0.016), but no difference in breast conserving rate. There
was no incidence of clinical congestive heart failure. However, this study does not demon‐
strate whether preoperative trastuzumab impact survival compared to using trastuzumab
postoperatively. Risk of cardiotoxicity and benefit of improving response are needed to be
discussed individually.
Recently, there are several clinical trials comparing the efficacy of emerging anti-HER2, la‐
patinib and pertuzumab, as its efficacy using with chemotherapy or the addition to trastu‐
zumab. The GeparQuinto trial compared the efficacy of lapatinib and trastuzumab, both
concurrently with chemotherapy in operable HER2-positive breast cancer [33]. The pCR rate
was significantly higher with the treatment of trastuzumab plus chemotherapy (30% vs 22%,
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p=0.04). However, breast conserving rate was not different and long-term outcomes are
awaited. With the hypothesis of using dual anti-HER2 might inhibit HER2 receptor more ef‐
ficiently, the clinical trials exploring the efficacy of dual anti-HER2, as neoadjuvant therapy
in HER2-positive breast cancer were developed. Dual anti-HER2, eg. Lapatinib or pertuzu‐
mab plus trastuzumab, did increase pCR rate, but did not increase breast conserving rate
compared to the patients who received trastuzumab plus chemotherapy. The studies of
HER2-targeted therapy combined with chemotherapy as neoadjuvant setting in HER2-posi‐
tive breast cancer are summarized in Table 1.
Studies N Treatment pCR (%) BCS (%)
Buzdar A et al*[32] 42 3wPx4->FECx4
Same CMT+H
26
65
53
57
NOAH*[34] 235 CMT
CMT+H 1 year
20
39
NA
Neosphere*[7] 417 D+T
D+T+P
T+P
D+P
29
46
17
24
NA
Neoaltto*[35] 455 L->wP
T->wP
L+H->wP
25
30
51
31
28
26
GeparQuinto*[33] 620 ECx4->Dx4+H
ECx4->Dx4+L
30
22
63
59
Abbrevations: N, number of patients; BCS, breast conserving rate; 3wP, Paclitaxel every 3 weeks; FEC, 5-FU+epirubicin
+cyclophosphamide;H, Trastuzumab; CMT, chemotherapy; D, docetaxel; P, pertuzumab; L, lapatinib; wP, weekly pacli‐
taxel; EC, epirubicin+cyclophosphamide; NA, not available; *The studies that reported significant different of pCR rate
and breast conserving rate.
Table 1. Neoadjuvant therapy in HER2-positive breast cancer
4.2. Bevacizumab combined with chemotherapy as a neoadjuvant therapy in HER2-
negative breast cancer
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, was shown
to improve response rate and progression-free survival when added to chemotherapy in meta‐
static HER2-negative breast cancer patients [36], [37]. Two recent phase III trials [38], [39] de‐
termined whether the addition of bevacizumab to chemotherapy would increase pCR rate in
HER2-negative operable breast cancer. Both studies confirmed that bevacizumab did increase
pCR rate. However, there was a controversial result whether which specific subgroups would
gain benefit from bevacizumab. It was claimed that bevacizumab added benefit in terms of
pCR in only triple-negative patients from GeparQuinto trial [39], whereas only patients with
positive estrogen receptor from the NSABP-B40 trial had higher pCR rate following bevacizu‐
mab treatment [38]. Because of contradictory results of these trials with premature long-term
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data as well as economic argument, therefore, bevacizumab is not recommended for neoadju‐
vant treatment in non-metastatic HER2-negative breast cancer.
4.3. Neoadjuvant endocrine therapy
Endocrine therapy has been used as a standard treatment in metastatic ER-positive breast
cancer with the objective response of 30-40 percent. Because of low profile of toxicity, it is
commonly used as the first option in low-risk metastatic breast cancer, ie asymptomatic,
long disease-free interval and limited metastatic disease. Conversely, neoadjuvant endocrine
therapy is not recommended as a standard of care because of its lower response rate com‐
pared with response rate in the study of neoadjuvant chemotherapy. The small studies re‐
ported response rate of 0-2 percent following tamoxifen [40], [41] and 2-3 percent after
aromatase inhibitor treatment [40], [42]. The studies of neoadjuvant endocrine therapy are
summarized in Table 2.
Studies N treatment ORR (%) BCS (%)
Eiermann et al*[43] 337 Letrozole
Tamoxifen
55
36
45
35
Smith et al [44] 330 Anastrozole
Tamoxifen
Combine
37
36
39
46
22
26
Ellis et al*[40] 324 Letrozole
Tamoxifen
60
41
48
36
Abbreviations; N, number of patients; ORR, overall response rate; BCS, breast conserving surgery rate; *The random‐
ized studies with the significant difference of overall response rate and breast conserving rate.
Table 2. Randomized trials comparing different neoadjuvant endocrine therapy
Although the objective response of primary endocrine treatment is not promising, endocrine
therapy remains a reasonable option in selected ER-positive breast cancer patients, for in‐
stance, the elderly patients who are not suitable for chemotherapy, or has organ function im‐
pairment, or desires to avoid adverse effect from chemotherapy. According to a randomized
study comparing the efficacy of neoadjuvant chemotherapy and aromatase inhibitor in post‐
menopausal ER-positive breast cancer patients, clinical response and pCR were not signifi‐
cantly different [45] . However, possibility of breast conserving surgery following primary
endocrine treatment is still infrequent.
With the rationale of the superiority of aromatase inhibitor to tamoxifen in metastatic set‐
ting of postmenopausal woman with breast cancer, the study of aromatase inhibitor in ne‐
oadjuvant  setting  compared  to  tamoxifen  has  been  performed.  Several  studies  showed
higher overall response rate and also breast conserving rate with aromatase inhibitor [40],
[43], [44] .
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At present, there are no data available about neoadjuvant endocrine therapy in premeno‐
pausal woman.
5. Predicting of response to NAC
Although, recent chemotherapeutic regimen for NAC treatment in breast cancer containing
anthracycline followed sequentially by a taxane can produces the good clinical response
rates [46]. A cPR is still less than 30% [46], [47]. However, these chemotherapeutic agents are
associated with significant morbidity. Therefore, the main benefit would be maximum if it
were possible to identify patients who are most likely to benefit from NAC before or shortly
after commencing the treatment. Recently, various biotechnologies, including both imaging
and biomolecular platforms, have been investigated in order to find novel biomarkers or
tests to predict responses to NAC. These technologies include molecular imaging, PET-CT,
scintigraphy, genomics and proteomic platforms [48]. However, there is not any promising
result demonstrated so far.
Amongst the above technologies, the most recent and feasible is the use of magnetic reso‐
nance imaging (MRI) as a early predictor of response to NAC. In a recent systematic review
study, where dynamic contrast enhanced (DCE) MRI performed pre and after 1-2 cycles of
NAC were compared, good sensitivity and specificity in predicting response to NAC was
demonstrated, depending on various MRI parameters used for interpretation. Substantial
reductions in tumour volumecould be accurate parameters in discriminating responders
and non-responders after 1-2 cycles of NAC [49].
PET-CT using 18 F-FDG seemed to be a good technology in predicting response to NAC due
to its combination of anatomical and functional characteristics of cancer cells. However, in a
small study comparing ability of PET-CT, MRI and ultrasonography in predicting response
to NAC, MRI was superior to PET-CT and ultrasonography [50].
6. Summary
With the rationale of NAC in term of controlling distant or micrometastasis, NAC should be
a good approach in breast cancer for both early and locally advanced disease. However, in
some early breast cancer, addition of chemotherapy might be an overtreatment with more
harmful than useful. Evidence from various clinical studies confirmed the benefit of NAC by
avoiding mastectomy in some responders. In the recent day, therefore, use of NAC is the
treatment of choice for locally advanced or some early breast cancer. Combination of NAC
and other targeted therapy such as trastuzumab have given even better outcome. Finally,
further research is still required in order to predict response to NAC as early as possible so
that patient who would not respond well to NAC could be identified early and would allow
seeking for the other treatment.
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